Research

Research structure

In line with the clinical translational cancer research strategy of the One NCT (six NCT sites across Germany), the research structure of the NCT/UCC Dresden is defined by three innovation pipelines:

  1. Precision Local Therapy, subdivided into Radiation Oncology and Surgical Oncology
  2. Cellular Immunotherapy
  3. Molecular Precision Oncology, with a focus on somatic and hereditary cancer

Innovative results generated within the pipelines are continuously transferred to multicentric clinical translational NCT trials. Trial design is successfully supported by patient representatives.

Diagram showing NCT/UCC Dresden innovation pipelines with three blue arrows labeled Precision Local Therapy, Cellular Immunotherapy, and Molecular Precision Oncology alongside a list of NCT priority research themes including diagnostic characterization, precision local therapy, molecularly targeted therapy, personalized immunotherapy, translational data science, fair patient access, and patient-reported outcome measurements
Research Structure of the NCT/UCC Dresden in alliance with the NCT Priority Research Themes (PRT).

In addition to these three main pipelines, Pediatric Oncology, Psychosocial Oncology, Patient reported outcome, and Clinical Artificial Intelligence build strong research programs across the innovation pipelines.

The NCT/UCC's strong Clinical Trial Infrastructure and Platforms supporting all three innovation pipelines, create an exceptional environment to facilitate the translation of highly personalized oncology on multiple levels.

Patient-oriented Priority Research Themes (PRT) and Priority Disease Areas (PDA) - defined by specific research fields and tumor entities - ensure the efficient and continuous transfer of interdisciplinary, personalized and innovative findings from bench to bedside and back.

All three innovation pipelines benefit from the portfolio of the NCT Overarching Clinical Translational Trial (OCT2) program, which supports the rapid transfer of scientific findings into clinical applications by funding clinically relevant, internationally competitive, cutting-edge science and translational clinical studies.